-
Europeiska läkemedelsmyndigheten (EMA) bekräftar positiv bedömning av nytto-riskbalansen för MULTAQ®
-
Sanofi Announces New Long Term Objectives
-
Sanofi Establishes a Global Agreement with Medco and UBC to Improve Quality of Patient Care through Real-World Evidence
-
Sanofi GetGoal Program on Lyxumia®, as an Add-on to Basal Insulin, Shows Significant Positive Phase III Results
-
Sanofi and DNDi - Drugs for Neglected Diseases initiative - Sign an Innovative Agreement to Generate New Drugs for Neglected Tropical Diseases
-
Data at ASCO Showcase Sanofi’s Commitment to Research and Identify Treatments for Cancer Patients
-
Nu blir Insuman Basal SoloSTAR det billigaste NPH-insulinet i förfylld penna
-
Ny studie visar på en signifikant minskning av antalet skov per år och uppbromsning av sjukdomsprogressen hos MS-patientersom byter till Copaxone® (glatirameracetat)
-
Lixisenatide Significantly Reduces HbA1c Without Increasing Hypoglycemia in Patients Uncontrolled on Sulfonylureas
-
Sanofi-aventis and its employees Donate to Tohoku Pacific Earthquake Relief Fund
-
Sanofi-aventis signs New Agreement with the World Health Organization (WHO) to fight Neglected Tropical Diseases
-
Sanofi-aventis Acquires from Ascendis Pharma Worldwide Rights on Drug-Delivery Technology in Diabetes and Related Disorders
Visa mer
Loading...